Cerebrovascular Diseases

Papers
(The H4-Index of Cerebrovascular Diseases is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Factors Associated with Discharge against Medical Advice among Acute Stroke Patients: Analysis of the Nationwide Emergency Department Sample38
Impact of RNF213 c.14576G>A Variant on the Development of Direct and Indirect Revascularization in Pediatric Moyamoya Disease26
Retraction Statement24
Normobaric Hyperoxia Combined with Endovascular Treatment in Patients with Acute Ischemic Stroke (OPENS-2) Trial: Protocol for a Prospective, Multicenter, Randomized Controlled Study23
Circadian Rhythm Disturbance in Acute Ischemic Stroke Patients and Its Effect on Prognosis22
Reply to the Letter to the Editor: Intraoperative Cortical Indocyanine Green Extravasation as a Predictor of Cerebral Hyperperfusion following Direct Revascularization for Moyamoya Disease – Impact of17
Rising Trends in Cerebrovascular Disease and Substance Use-Related Mortality in the USA from 1999 to 2020: A Retrospective Analysis Using CDC WONDER17
Intensive Blood Pressure Lowering and Renal Function in Ischemic Stroke Patients: Secondary Analysis of the ENCHANTED Trial16
Asia Pacific Stroke Conference 2024 Combined Australian and New Zealand Stroke Organisation Conference15
A Global Health Perspective on the 2026 AHA/ASA Stroke Guidelines: Lessons from the Indian Health System15
Development and Validation of a Prediction Model for 30-Day Mortality and Functional Outcome in Patients with Primary Brainstem Hemorrhage14
9th World Intracranial Hemorrhage Conference (WICH) 2025, Wesley Conference Centre, Sydney, Australia, March 28-29, 2025: Abstracts14
Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes with Alteplase at 0.6 mg/kg in Clinical Practice: THAWS2 Study12
Variation in Ischemic Stroke Payments in the USA: A Medicare Beneficiary Study12
0.18646597862244